<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02810808</url>
  </required_header>
  <id_info>
    <org_study_id>13411950400</org_study_id>
    <nct_id>NCT02810808</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD</brief_title>
  <acronym>ARTIS</acronym>
  <official_title>Random, Open-label Multicenter, Phase IV Study Assessing the Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eye &amp; ENT Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the efficacy and safety of two different dosing regimens of
      ranibizumab (0.5 mg on BCVA by 1+PRN vs 3+PRN) in Chinese patients with wet AMD. This study
      is to provide long-term safety data in the treatment of Chinese patients with wet AMD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion Criteria： Age ≥ 50 y/o, nAMD patients（including PCV） Best-corrected visual
      acuity（BCVA） Exclusion Criteria： Previous anti-VEGF treatment within 3 months History of
      intraocular surgery within 3 months or arrangement of intraocular surgery in the next 6
      months from baseline Active or recent intraocular inflammation in the study eye Primary
      Endpoint： Improvement in BCVA compared to baseline Other： Central Macular Thickness after
      Treatment，Numbers of Injections
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Snellen BCVA at every visit</measure>
    <time_frame>12 months</time_frame>
    <description>Compare of mean Snellen Best-Corrected-visual-acuity and mean central macular thickness by OCT at every visit or treatment between the two groups to assess the efficacy of 1+PRN of Ranibizumab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Compare of Number of participants with treatment-related adverse events between the two groups to assess the safety of 1+PRN of Ranibizumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of injections in 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Compare of mean number of injection in 12 months between the two groups to assess the efficacy of 1+PRN of Ranibizumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean central macular thickness at every visit by OCT</measure>
    <time_frame>12 months</time_frame>
    <description>Compare of mean central macular thickness by OCT at every visit between the two groups to assess the efficacy of 1+PRN of Ranibizumab.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Ranibizumab 0.5 mg 1+PRN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization in the 11 month treatment period Intervention: Drug: Ranibizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranibizumab 0.5 mg 3+PRN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization after three Monthly intravitreal injections of the same dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>1+PRN</intervention_name>
    <description>PRN intravitreal injections of Ranibizumab 0.5mg guided by BCVA stabilization after the injection of the same does at the first month.</description>
    <arm_group_label>Ranibizumab 0.5 mg 1+PRN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>3+PRN</intervention_name>
    <description>PRN intravitreal injections of Ranibizumab 0.5mg guided by BCVA stabilization after the first three monthly intravitreal injections of the same does.</description>
    <arm_group_label>Ranibizumab 0.5 mg 3+PRN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Ranibizumab — a recombinant, humanized monoclonal antibody Fab that neutralizes all active forms of VEGF-A was recently approved by the Food and Drug Administration for the treatment of all angiographic subtypes of subfoveal neovascular age-related macular degeneration</description>
    <arm_group_label>Ranibizumab 0.5 mg 1+PRN</arm_group_label>
    <arm_group_label>Ranibizumab 0.5 mg 3+PRN</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed-consent before any evaluation

          -  Visual impairment due to active CNV,including predominantly classic CNV,minimally
             classic CNV,occult CNV with no classic component and PCV.

          -  50 years old and older

          -  Chinese

          -  For study eye: screening and baseline BCVA scores both should be between 78 and 23
             words (including 78 and 23 words) (approximately equals to 20/30-20/320 sneeleen
             vision chart units) while tested at 4 meters with ETDRS vision chart.

        Exclusion Criteria:

          -  Have Stroke and myocardial infarction within 3 months before screening

          -  Any active periocular and ocular infection and inflammation (including blepharitis,
             conjunctivitis, keratitis, scleritis, uveitis, intraocular inflammation) while
             screening and baseline.

          -  Uncontrolled glaucoma (under treatment [IOP] ≥ 30 mm Hg or depend on researchers)
             while screening and baseline

          -  Neovascularization of iris and neovascular glaucoma while screening and baseline

          -  Any causes led to choroidal neovascularization except Wet AMD (including ICNV,central
             serous chorioretinopathy,ocular histoplazmoza and pathologic myopia) while screening
             and baseline

          -  With structure injury (including vitreous macular traction,epiretinal membrane
             involving in central fovea,subretinal fibroplasia,laser scar and central fovea
             atrophy) within 0.5 optic disc diameter to the central of macula while screening and
             baseline, which may harm the improvement of vision by treatment according to
             researchers

          -  Any systemic anti-VEGF medication(as Avastin) use within 3 months before screening

          -  Any medication systemic use toxic to lens, retina and optic nerve,including iron
             amine, chloroquine/chloroquine (Plaquenil ®), tamoxifen, phenothiazine and ethambutol

          -  For study eye：Used to accept following treatments for wet AMD within 3 months or
             accept following treatments more than three times before baseline: a)Anti-angiogenesis
             drugs(pegaptanib （Macugen®），ranibizumab
             ,bevacizumab（Avastin®),VEGF-Trap，KH902；b）Anecortave acetate corticosteroids；c）Protein
             kinase C inhibitors，squalamine，siRNA; d)PDT （Visudyne®）treatment,external beam
             radiotherapy, local laser photocoagulation, vitrectomy, submacular surgery and
             transpupillary thermotherapy

          -  Any intraocular surgery(including YAG laser) within 3 months before baseline or
             predicated within 6 months after baseline

          -  Intraocular or periocular treatment of corticosteroids within 3 months before baseline

          -  For follow eye:Any anti-angiogenesis treatment(including anti-VEGF,like
             Lucentis,Avastin® and KH902 ) within 3 months before baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaodong Sun, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai General Hospital, Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaodong Sun, M.D.</last_name>
    <phone>+86-02163240090</phone>
    <phone_ext>6822</phone_ext>
    <email>xdsun@sjtu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eye &amp; Ent Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Chang, M.D.</last_name>
      <phone>+8613916827595</phone>
      <email>qingchang@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai 10th People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fang Wang, M.D.</last_name>
      <phone>+8618917683335</phone>
      <email>dreyemilwang_122@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai First People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaodong Sun, M.D.</last_name>
      <phone>+86 21 63240090</phone>
      <phone_ext>6822</phone_ext>
      <email>xdsun@sjtu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Xiaodong Sun, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fei Yuan, M.D.</last_name>
      <phone>+8613816852158</phone>
      <email>yuan.fei@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peiquan Zhao, M.D.</last_name>
      <phone>+8613311620396</phone>
      <email>zhaopeiquan@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Friedman DS, Katz J, Bressler NM, Rahmani B, Tielsch JM. Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey. Ophthalmology. 1999 Jun;106(6):1049-55.</citation>
    <PMID>10366070</PMID>
  </reference>
  <reference>
    <citation>Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE, Hofman A, Jensen S, Wang JJ, de Jong PT. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology. 2001 Apr;108(4):697-704.</citation>
    <PMID>11297486</PMID>
  </reference>
  <reference>
    <citation>Hsu WM, Cheng CY, Liu JH, Tsai SY, Chou P. Prevalence and causes of visual impairment in an elderly Chinese population in Taiwan: the Shihpai Eye Study. Ophthalmology. 2004 Jan;111(1):62-9.</citation>
    <PMID>14711715</PMID>
  </reference>
  <reference>
    <citation>Miyazaki M, Nakamura H, Kubo M, Kiyohara Y, Oshima Y, Ishibashi T, Nose Y. Risk factors for age related maculopathy in a Japanese population: the Hisayama study. Br J Ophthalmol. 2003 Apr;87(4):469-72.</citation>
    <PMID>12642312</PMID>
  </reference>
  <reference>
    <citation>Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1419-31.</citation>
    <PMID>17021318</PMID>
  </reference>
  <reference>
    <citation>Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1432-44.</citation>
    <PMID>17021319</PMID>
  </reference>
  <reference>
    <citation>Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009 Jul;148(1):43-58.e1. doi: 10.1016/j.ajo.2009.01.024. Epub 2009 Apr 18.</citation>
    <PMID>19376495</PMID>
  </reference>
  <reference>
    <citation>Tano Y, Ohji M; EXTEND-I Study Group. EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Acta Ophthalmol. 2010 May;88(3):309-16. doi: 10.1111/j.1755-3768.2009.01843.x. Epub 2010 Feb 16.</citation>
    <PMID>20163368</PMID>
  </reference>
  <reference>
    <citation>CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19;364(20):1897-908. doi: 10.1056/NEJMoa1102673. Epub 2011 Apr 28.</citation>
    <PMID>21526923</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Xiaodong Sun</investigator_full_name>
    <investigator_title>Professor and Executive Vicechair of Department of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Neovascular Age-related Macular Degeneration</keyword>
  <keyword>Ranibizumab</keyword>
  <keyword>Pro Re Nata</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

